Zynerba is conducting clinical studies of Zygel™ in a number in patients with a number of neuropsychiatric conditions the United States and Australia/New Zealand. Zygel is an experimental treatment. This means that it is not approved by government regulatory bodies, including the United States Food and Drug Administration (FDA) and other agencies and must be tested to see if it is an effective and safe treatment.
CONNECT-FX (Clinical Study of Cannabidiol (CBD) in Children and Adolescents with Fragile X). Update: Enrollment complete
BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder). Update: Enrollment complete
INSPIRE (Assessing the Impact of Zygel [Transdermal CBD Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome). Enrollment ongoing
Read more about Zynerba’s clinical pipeline here.